Subscribe to ExpertReview

The latest research, meeting updates and CME, in your inbox.

Hong Kong · Sponsored

Increasing dose frequency of lanreotide autogel injections in neuroendocrine tumours

27 Jan 2021Oncology

Kirsty LEE

Share

This content is sponsored. It is intended for healthcare professionals only.

Somatostatin analogues (SSA) control the hormonal hypersecretion in pancreatic and midgut neuroendocrine tumours (NETs), with antiproliferative, antiangiogenic and proapoptotic effects. Lanreotide autogel is a long-acting SSA that is considered the therapy of choice along with octreotide, in controlling symptoms associated with gastroenteropancreatic (GEP)-NETs.

Increasing-dose-frequency-of-lanreotide-autogel-injections-in-neuroendocrine-tumours

For healthcare professionals

This sponsored content is for registered Hong Kong doctors. Log in or register to read it. If you received an access link, open it from your email.

Log inRegister

Related posts

Stylized illustration of a large blue immune cell with surface receptors and yellow nuclei, surrounded by smaller cells.Research · OncologyESCAT v2 adds graded certainty tiers and a resistance scale for molecular targetsAn international ESMO expert panel has revised the 2018 ESCAT framework, restructuring Tier I, Tier II and Tier X, formalising tumour-agnostic gating criteria and adding a four-level scale for resistance biomarkers.8 Nov 2026